Verve Therapeutics
Agent42Agent Readiness: 42/100. Above median. Measured by StartupHub.ai. Median 41.Trust64Data Trust: 64/100. Above median. Measured by StartupHub.ai. Median 61.Developing gene editing therapies to lower cholesterol.
About
Verve Therapeutics is a biotechnology company focused on developing novel gene editing therapies to address cardiovascular disease. Their lead candidate, VERVE-102, is an experimental gene-editing therapy designed to permanently lower LDL cholesterol (bad cholesterol) after a single infusion. The therapy works by targeting PCSK9, a gene that plays a key role in regulating cholesterol levels.
Listed competitors
A clinical-stage biotechnology company developing transformative genome editing medicines for serious diseases.
A biotechnology company developing precision genetic medicines through base editing technology to treat a broad range of diseases.
A clinical-stage genome editing company developing novel therapies using CRISPR/Cas9 technology for severe diseases.
Also in this space
Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
Shares Biotechnology, Biotech
Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).
Shares Biotechnology, Biotech
Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.
Shares Biotechnology, Drug Discovery
Freenome is a biotechnology company developing a multi-cancer early detection blood test using machine learning and biology.
Shares Biotechnology, Biotech
A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.
Shares Biotechnology, Biotech
Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.
Shares Biotechnology, Drug Discovery
Key facts
- Website
- vervetx.com
- Headquarters
- Cambridge, Massachusetts, USA
- Founded
- 2018
- Total funding
- $290M (Series B)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 1 Jun 2021 | Series B | $215M | Fidelity, Arch Venture Partners |
| 1 Jun 2020 | Series A | $75M | Arch Venture Partners |
Tech stack
Detected on vervetx.com, last scanned 21 Sept 2026. Run your own scan
- CDN
- Cloudflare
- Email provider
- Microsoft 365
Verve Therapeutics scores 54. Does yours?
That is its Ahrefs DR: the backlink strength of a domain, on the Ahrefs 0 to 100 scale. Paste your website and you get yours in about a minute.
Frequently asked
What does Verve Therapeutics do?
Early clinical trial results have shown promising safety and efficacy, with significant reductions in LDL cholesterol observed.
Is Verve Therapeutics trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Verve Therapeutics is 64 out of 100, a generally safe rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has Verve Therapeutics raised?
Verve Therapeutics has raised a total of $290M in funding. The most recent round on record is Series B.
Public record
SEC filings, insider activity, nonprofit links and pay benchmarks for Verve Therapeutics
